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In the last decades, transcatheter aortic valve replacement (TAVR) revolutionized the
treatment of symptomatic severe aortic stenosis. The efficacy and safety of TAVR were
first proven in inoperable and high-risk patients. Then, subsequent randomized clinical
trials showed non-inferiority of TAVR as compared to surgical aortic valve replacement
also in intermediate- and low-risk populations. As TAVR was progressively studied and
clinically used in lower-risk patients, issues were raised questioning its opportunity in a
younger population with a longer life-expectancy. As long-term follow-up data mainly
derive from old studies with early generation devices on high or intermediate surgical risk
patients, results can hardly be extended to most of currently treated patients who often
show a low surgical risk and are treated with newer generation prostheses. Thus, in this
low-risk younger population, decision making is difficult due to the lack of supporting
data. The aim of the present review is to revise current literature regarding TAVR in
younger patients.
Keywords: transaortic valve replacement, TAVR, severe aortic stenosis, valvular heart disease, young patients,
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INTRODUCTION
Aortic stenosis (AS) is the most common valvular heart disease in the adult population and its
prevalence progressively increases according to population aging (1). Medical therapy yields poor
outcomes in severe symptomatic AS treatment and surgical aortic valve replacement (SAVR) has
long been considered the standard of care in suitable symptomatic patients with severe AS (2). The
development of transcatheter aortic valve replacement (TAVR) provided a new strategy for their
treatment that rapidly became a valid alternative approach in a progressively larger proportion of
patients. From the interventional perspective, the procedure of TAVR has significantly evolved over
the years. From the very first pioneering implant by Cribier, performed through a trans-venous,
trans-septal, retrograde approach (3), nowadays procedural steps have been clearly defined.
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The percutaneous transfemoral approach performed under local
anesthesia with conscious sedation is the most widely adopted in
current practice, due to its easiness, low invasiveness and better
short- and long-term outcomes (4, 5).
Aim of the present review is to revise the history of TAVR by
focusing on its adoption in “young” patients and address current
open issues regarding TAVR in this group.
THE EVOLUTION OF TAVR
From Young to Old and Back to Young
Patients
The first-in-man TAVR procedure was performed on a
middle-aged patient. Back in 2002, Professor A. Cribier
implanted a prototype balloon expandable valve on a 57-year-
old man with severe calcific AS who was judged inoperable
due to hemodynamic instability and significant associated
comorbidities (3). The technical success of this procedure laid
the foundation for subsequent studies investigating TAVR in
inoperable and high-risk surgical candidates so as to offer a
therapeutic option for such critical patients.When comparing the
development of TAVR to the evolution of percutaneous coronary
interventions it is clear that their development moved in opposite
directions. While coronary interventions were first performed
in extremely selected low-risk patients moving to higher-risk
challenging cases (6), TAVR first focused on older, high/extreme
surgical risk patients, and gradually approached younger and
lower-risk subjects.
In this context, indication to TAVR was judged according to
surgical risk scores such as the Society of Thoracic Surgeons
(STS) score or the EuroScore (ES), both estimating the risk of
30-days mortality after open surgery.
According to the STS score, three categories of patients were
identified, namely at high, intermediate or low risk (> 8%, 4–8%,
or <4%, respectively), with only slight variations of the cut-off
values among the studies or the less precise EuroScore II (7).
Nevertheless, due to the limited numbers of criteria considered as
variables in conventional surgical risk scores and their derivation
from surgical series, the STS score and the EuroScore II have been
proven to perform poorly in patients undergoing TAVR, thus
highlighting the utmost role of appropriate clinical judgment in
the choice between surgical vs. interventional approaches (8).
The Evolution of TAVR: A Path Through
Randomized Clinical Trials and Registries
The first randomized controlled trial on TAVR, the PARTNER
1B, was published in 2010 and compared TAVR with a
balloon-expandable bovine pericardial Edwards SAPIEN Valve
against medical therapy on extreme-risk patients (mean age
83.1 ± 8.6 years, mean STS score 11.2 ± 5.8). The trial
reported a significantly lower rate of death at 1 year in the
TAVR group compared to the medical treatment group, thus
opening this therapeutic possibility (9). The evidence that a
percutaneous treatment in non-surgical candidates was superior
to standard medical therapy laid the ground for the subsequent
PARTNER 1A trial, demonstrating the non-inferiority of TAVR
vs. SAVR in high-risk patients (10). In parallel, the efficacy
of the self-expandable Medtronic CoreValve bioprosthesis was
demonstrated in non-operable as well as high-risk patients with
the CoreValve Extreme risk study and the CoreValve High risk
trial, respectively (11, 12).
In the following years, trials comparing, TAVR vs. SAVR
on intermediate-risk patients demonstrated the non-inferiority
of TAVR vs. SAVR with both the second generation balloon-
expandable SAPIEN XT valve in the PARTNER 2A trial and
the self-expandable CoreValve valve in the SURTAVI trial (13,
14). Recently, TAVR was evaluated in low-risk patients, with
the PARTNER 3 trial showing the superiority of the balloon-
expandable SAPIEN 3 valve compared to SAVR and the Evolut
Low Risk Trial demonstrating non-inferiority against SAVR.
(12, 15) Characteristics of the landmark TAVR trials are reported
in Table 1.
The consistent reduction of the estimated surgical risk
throughout the years in trials’ populations paralleled the
reduction in the mean age (with an inverse increase in expected
survival) of patients enrolled in the different trials (from mean
age 83.1 ± 8.6 years in the PARTNER IB to mean age 74.0 ±
5.9 years in the Evolut Low Risk Trial), as age represents one
of the main determinants of surgical risk. This trend clearly
urges to consider several aspects of TAVR, such as procedural
safety, long term efficacy, freedom from reinterventions, and
patient’s expectations, all of which have tremendous impact when
evaluating different therapeutic options in young patients with
severe AS.
The outspread performance of TAVR procedures boosted by
the promising trials’ results fueled the birth of national registries,
providing encouraging TAVR data on wider populations in real-
life scenarios (16–21). The progressive trend in lowering of
the surgical risk of the TAVR patients included in randomized
trials was also evident in real life all-comers registries (18, 20).
When only low-risk patients were considered, the mean logistic
EuroScore decreased down to 10.8% (21). Overall, the mean
age of patients enrolled in TAVR registries remained stable at
about 80–82 years across all reports, but more attention has
been recently given to younger patients, with latest data focusing
specifically on this peculiar population (22). Basic features of
TAVR registries are reported in Table 2.
While only few studies specifically focused on younger
patients, current randomized trials enrolled patients according
their high or intermediate surgical risk, thus intrinsically
selecting elderly patients. This is evident when considering that
mean age only decreased from 83 years in the PARTNER 1B trial
to 73 years in the PARTNER 3 trial despite a concomitant drop in
STS score from 11.2% down to 1.9% (9, 15).
Beside age and surgical risk, several clinical parameters, such
as myocardial fibrosis, renal dysfunction, diabetes mellitus and
pulmonary hypertension, have been identified as predictors short
term all-cause mortality (23–25).
While only, preliminary evidence is currently available
supporting the treatment of younger patients, patients requests
for a percutaneous treatments in particular in younger subjects
are becoming a matter of daily negotiation. The initial data
deriving from the AQUA registry, addressing symptomatic































TABLE 1 | Characteristics of the landmark studies on transcatheter aortic valve replacement.
Study Year Population Arms Age Risk scores Results Complications
Extreme-risk
PARTNER B 2010 358 pts with
severe AS, NYHA








83.1 ± 8.6 STS score 11.2%
EuroScore 26.4%
TAVR significantly reduces the rate of all-cause
death (HR 0.55), CV death (HR 0.39), death +
rehospitalization (HR 0.46), symptoms and
6MWD at 1 yr and non-significantly increases
major stroke rate at 30 days (5.0 vs. 1.1%, p
0.06) and 1 yr (7.8 vs. 3.9%, p 0.18).
Paravalvular aortic regurgitation 3–4+ in TAVR:
11% at 30 days and 1 yr
CoreValve Extreme
Risk
2014 489 pts with
severe AS, NYHA





vs. OPG (43% for
all-cause death or
stroke at 1 yr)
83.2 ± 8.7 STS score 10.3%
EuroScore 22.6%
All-cause death or stroke at 1 yr 26.0% (upper
95%CI 29.9% < OPG 43%). Significant
improvement in NYHA class
PM implantation: 21.6% at 30 days, 26.2% at
1 yr. Paravalvular aortic regurgitation 3–4+: 4%
at 1 yr
High-risk
PARTNER A 2011 699 pts with
severe AS, NYHA
II-IV, STS > 10%
TAVR with Edwards
SAPIEN valve vs. SAVR
83.6 ± 6.8 STS score 11.8%
EuroScore 29.3%
No difference in all-cause death at 1 yr (24.2%
TAVR vs. 26.8% SAVR). More neurological
events (strokes + TIA) in TAVR pts at 30 days
and 1 yr (p 0.04). Shorter hospital stay and
shorter ICU stay in TAVR patients
Higher rate of vascular complications at 30
days in TAVR. No difference in new PM
implantation (4%). More major bleeding events
and new-onset AF in SAVR
CoreValve High
Risk





83.2 ± 7.1 STS score 7.3%
EuroScore 17.6%
TAVR reduces 1 yr all-cause death (14 vs. 19%,
p 0.04) and neurological events (20 vs. 27%)
More PM implantations and major vascular
complications in TAVR. More bleeding events,
AKI and new or worsening AF in SAVR
Intermediate-risk




TAVR with SAPIEN XT
vs. SAVR
81.5 ± 6.7 STS score 5.8%
EuroScore N/A
No difference in primary composite endpoint
(all-cause death + disabling stroke) at 2 yrs;
similar single components of the primary
endpoint. TF TAVR reduces the primary
endpoint (HR 0.78, p 0.05)
More major vascular complications and
paravalvular aortic regurgitation but less
life-threatening bleeding, AKI, and new-onset
AF in TAVR. Similar new PM implantation rates
(8.5 vs. 6.9%, p 0.17)





TAVR with CoreValve or
Evolut R vs. SAVR
79.8 ± 6.2 STS score 4.4%
EuroScore 11.9%
TAVR non-inferior for composite primary
endpoint (all-cause death + disabling stroke) at
2 yrs. No structural valve deterioration at 2 yrs
in both groups
Higher aortic regurgitation (5%) and new PM
implantation (26 vs. 7%) in TAVR. Higher AKI
(4%), AF (43%) and blood transfusions in SAVR
Low-risk





79.2 ± 4.9 STS score 2.9%
EuroScore 8.4%
TAVR non-inferior for composite primary
endpoint (all-cause death + stroke + MI) at 1 yr
TAVR showed fewer post-operative major
bleedings, cardiogenic shock, AKI and new AF,
and shorter hospital stay. At 1 yr, TAVR showed
more PM implantations, total aortic
regurgitation, and higher NYHA class
Evolut Low Risk 2019 1,403 pts with
severe AS, NYHA
II-IV, STS < 3%
CoreValve or Evolut R
or Evolut PRO TAVR
vs. SAVR
74.0 ± 5.9 STS score 1.9%
EuroScore N/A
TAVR non-inferior for composite primary
endpoint (all-cause death + disabling stroke) at
2 yrs
TAVR shows fewer 30-days disabling strokes,
bleeding complications, AKI, and AF but higher




























































































TABLE 1 | Continued
Study Year Population Arms Age Risk scores Results Complications







TF TAVR with SAPIEN
3 vs. SAVR.
73.3 ± 5.8 STS score 1.9%
EuroScore II 1.5%
TAVR non-inferior for composite of all-cause
death, stroke, and rehospitalizations at 2 yrs
(HR 0.54, p 0.001). TAVI shows lower 30-days
stroke (HR 0.25), death or stroke (HR 0.30) and
new AF (HR 0.10), shorter index hospitalization,
fewer major bleeding events (HR 0.12) but
more new left bundle branch block (HR 3.43)
No difference in major vascular complications
and new PM implantation rates at 30 days, nor
in 3–4+ aortic regurgitation at 30 days or 1 yr
UK TAVI 2020 913 pts with
severe AS, aged ≥




TAVR vs. SAVR 81.1 ± 4.4 STS score 2.6%
EuroScore N/A
TAVR non-inferior for all-cause death (HR 1.91,
p 0.33), CV death (HR 2.22, p 0.27), stroke (HR
0.95, p 0.93), or the composite of all-cause
death + stroke (HR 0.95, p 0.88) at 1 yr
compared to SAVR
TAVR is associated with less major bleeding,
shorter hospital stay, and more rapid
improvement in NYHA class and QoL as well
as more vascular complications, PM
implantations, and mild or moderate aortic
regurgitation than SAVR.
Direct comparison
CHOICE 2014 241 pts with
severe AS, NYHA
II-IV, high surgical
risk (≥ 75 yo or












81.9 ± 6.7 STS score 5.6%
EuroScore 21.5%
Device success was more frequent in the
balloon-expandable group compared to the
self-expanding group (RR 1.24, p < 0.001).
Significantly lower moderate to severe aortic
regurgitation, less frequent need for implanting
more than 1 valve, and fewer PM implantations
in the balloon-expandable valve group.
Cardiovascular mortality and bleeding and
vascular complications were not significantly
different








82.8 ± 4.1 STS score 3.5%
EuroScore N/A
Non-inferiority of the ACURATE neo was not
met as for the primary composite efficacy and
safety endpoint (absolute risk difference 7.1%,
p 0.42) at 30 days compared to SAPIEN 3.
More frequent AKI and moderate or severe
aortic regurgitation with ACURATE neo. No
difference in all-cause death and stroke
between the study groups.




Evolut R TAVR systems
83.2 ± 4.3 4.6 ± 2.9% Non-inferiority of the ACURATE neo was not
met as for the primary composite endpoint
(absolute risk difference 1.8%; p=0.0549) at 1
year compared to Evolut R
More frequent cardiac deaths, moderate or
severe aortic regurgitation at 30 days while
lower PM implant rate were observed in the
ACURATE neo group




TF TAVR with SAPIEN
3 vs. Evolut R
81.7 ± 5.3 STS score 4.7%
EuroScore 15%
No difference in composite of all-cause death,
stroke, 3–4+ paravalvular leak and permanent
PM implantation at 30 days (28.4 vs. 26.1%, p
0.04 for equivalence). No difference in
individual components of the primary endpoint
PM implantation rates SAPIEN 3 19% vs.
Evolut R 23% (p 0.06 for equivalence).
Numerically higher strokes with SAPIEN 3 (4.7
vs. 0.5%, p 0.003 for equivalence)
6MWD, 6-min walking distance; AF, atrial fibrillation; AKI, acute kidney injury; AS, aortic stenosis; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ICU, intensive care unit; MI, myocardial infarction; N/A, not available; NYHA,
New York Heart Association; pts, patients; OPG, objective performance goal; PM, pace maker; QoL, quality of life; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TF, transfemoral; TIA, transient ischemic


























































































TABLE 2 | Characteristics of the published registries on transcatheter aortic valve replacement.
Registry Year Country Population Age Risk scores Results Complications
FRANCE 2 2012 France 4,165 pts undergoing
TAVR between 2010
and 2012
82.8 ± 7.1 EuroScore 21.7% In-hospital mortality rate 8.1% and
30-days mortality rate 10.1%. Discharge
by day 5 post-TAVR 11.9%
Stroke rate 2.0%. Permanent PM implantation
12.6%. Paravalvular aortic regurgitation 3–4+
15.7%




83.4 ± 7.2 EuroScore 17.9% (p <
0.001)*
In-hospital mortality rate 4.9 % (p <
0.001)* and 30-days mortality rate 5.4% (p
< 0.001)*. Discharge by day 5 post-TAVR
24.7% (p < 0.001)*
Stroke rate 2.0% (p 0.82)*. Permanent PM
implantation 17.5% (p < 0.001)*. Paravalvular aortic
regurgitation 3–4+ 10.2% (p < 0.001)*
GARY -
intermediate risk
2018 Germany 7,613 pts undergoing
isolated TAVR or SAVR
for severe AS between
2012 and 2014, STS
4.0–8.0%
82.5 ± 5.0 STS score 5.6%
EuroScore 21.2%
No difference in in-hospital mortality (3.6
vs. 3.6%, p 0.976) and
propensity-matched 1-year mortality (17.1
vs. 15.7%, p 0.59) between TAVR and
SAVR
No difference in in-hospital major stroke (1.4 vs.
1.0%, p 0.201) between TAVR and SAVR. More
new PM (18.1 vs. 4.0%, p < 0.001), vascular
complications (7.8 vs. 0.9%, p < 0.001) and aortic
regurgitation ≥2+ (4.3 vs. 0.5%, p < 0.001) in
TAVR. Higher rate of postprocedural bleeding
requiring transfusion (22.1 vs. 59.6%, p < 0.001) or
reintervention (1.0 vs. 4.7%, p < 0.001) and
temporary dialysis (1.8 vs. 6.5%, p < 0.001)
in SAVR.
SWISS TAVI 2018 Switzerland 4,599 pts undergoing
TAVR between 2011
and 2016
82.2 ± 6.3 STS score 5.5%
EuroScore 18.2%
30-days mortality 3.8% and 1-year
all-cause mortality 13% and
cardiovascular mortality 9.0%
30-days new PM 18.5%, AKI 4.8%, disabling stroke
1.9%, major bleeding 7.3%. 1-year new PM 20.2%,
MI 0.9%, disabling stroke 2.6%, major bleeding
8.3%
UK TAVI 2018 United Kingdom 13,198 pts undergoing
TAVR between 2007
and 2016
82 EuroScore 18.5% Decline in in-hospital mortality from 4.7%
in 2013 down to 1.8% in 2016
Stroke rate 2%, dyalisis requirement <1% in 2016
AQUA 2018 Germany 6,974 pts aged 65–74
yrs undergoing
TF-TAVR or isolated
SAVR in 2013 and
2014
71.6 ± 2.5 EuroScore 12.2% After propensity-matching, no difference in
in-hospital mortality (1.3 vs. 1.9%, p 0.39),
stroke/TIA (1.0 vs. 2.1%, p 0.09) and MI (0
vs. 0.3%, p 0.16) between TF-TAVR and
SAVR. Shorter postoperative hospital stay
after TF-TAVR (9.5 vs. 12.5 days after
SAVR, p < 0.001)
More frequent PM implantation after TF-TAVR (13.3
vs. 3.5%, p < 0.001). More frequent postoperative
delirium after SAVR (8.9 vs. 2.4%, p < 0.001).
GARY –low risk 2019 Germany 20,549 pts undergoing
isolated TAVR or SAVR
for severe AS in 2014
and 2015, STS < 4.0%
78.9 ± 5.6 STS score 2.9%
EuroScore 12.9%
Higher in-hospital and 30-days survival in
TAVR patients than SAVR (98.5 vs. 97.3%,
p = 0.003; 98.1 vs. 97.1%, p = 0.014).
No difference in 1-year survival (90.0 vs.
91.2%, p = 0.158)
TAVR associated with more frequent PM
implantation (15.1 vs. 4.4%, p < 0.0001), vascular
complications (2.2 vs. 0.5%, p < 0.0001) and aortic

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































patients younger than 75 years-old with an average intermediate
surgical risk (EuroScore 12.2%), reported similar in-hospital
outcomes for TAVR and SAVR with the exception of a more
frequent need for new pacemaker implantation and a less
frequent incidence of postoperative dialysis and delirium in
TAVR (22).
Beside the progressive extension of TAVR to lower risk,
younger populations, current research is focused on head to head
comparisons between different transcatheter devices in order to
ascertain the best fit between patient and current commercially
available prostheses. Table 1 reports details on currently available
direct comparisons between different devices (26–29). The results
of recent trials support the safe implantation of newer generation
valves, which have the advantage of better adaptation to the
individual valve anatomy (26).
IT IS NEVER TOO LATE TO BE YOUNG:
TAVR IN “YOUNG” PATIENTS
Apart from rare congenital cardiovascular diseases, severe AS
is commonly diagnosed in middle-aged and elderly patients. By
“young” AS patients we define individuals between 60 and 75
years of age, who have been only marginally included in current
TAVR trials but might personally prefer or deserve percutaneous
approach according to peculiar clinical characteristics. In our
practice, we encountered three different groups of young patients
in whom TAVR might be considered as an alternative to surgery,
namely asymptomatic active patients with degenerative AS on a
tricuspid valve, severe AS patients on a bicuspid aortic valve and
severely comorbid “young” patients with severe AS unsuitable
for the traditional surgical approach (i.e., the “Cribier’s patient”)
(Figure 1).
Asymptomatic Patients
As new severe AS therapy opportunities were put forward and
guidelines indications were updated, doubts and controversies
were raised regarding the treatment of asymptomatic patients
(1). While no data are yet available to support the treatment
of asymptomatic AS patients with TAVR, some evidence
is becoming available for SAVR. The recent RECOVERY
trial compared early SAVR vs. conservative management in
asymptomatic patients with severe AS (mean age 63.4 ± 10.7
years) and highlighted a significantly lower incidence of operative
mortality or cardiovascular death in the early intervention group
(30). The mean age of patients included in this trial clearly
highlights that severe AS is not unique to elderly patients.
Likewise, propensity-matched data from CURRENT AS registry
stress that early aortic valve replacement (98% SAVR, mean age
71.6 ± 8.7 years) provides better 5-years survival and fewer
heart failure hospitalizations compared to conservative strategies
(31). Following the RECOVERY trial and the CURRENT AS
registry, a meta-analysis encompassing a total of 29 observational
studies with 4,075 patients showed high rates of all-cause death,
cardiac death and progression to aortic valve intervention in
untreated patients and demonstrated that early AS intervention
was associated with a significant reduction in long-termmortality
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FIGURE 1 | Pros and cons of transcatheter aortic valve replacement in young patients.
(HR 0.38; 95%CI 0.25–0.58) compared to a conservative strategy
(32). These studies mostly comprised SAVR-treated patients in
the intervention group. If similar results were confirmed with a
percutaneous approach, it would pave the road to a paradigm
shift from a symptomatic approach to “prophylactic” treatment
of severe AS in the absence of symptoms.
It is common knowledge that a certain number of
asymptomatic severe AS patients are currently treated with
TAVR despite the lack of strong supporting evidence derived
from dedicated studies. The paucity of limiting symptoms and
their relative younger age usually allow these patients to be still
professionally or physically active. In addition, asymptomatic
subjects might have reduced perception of the valvular disease,
thus preferring or accepting only a percutaneous solution
able to shorten their absence from professional and personal
duties as compared to conventional surgery. Clearly, when
referring asymptomatic patients to TAVR procedural safety and
long-term efficacy must be warranted in order not to dissipate its
clinical benefit.
Research is moving faster to address unresolved issues
regarding young AS patients. From a physiological and structural
point of view, myocardial fibrosis represents a key progressive
phase in left ventricular hypertrophic response to severe AS and
its detection at late gadolinium enhancement cardiac magnetic
resonance was proved to be an independent predictor of all-
cause mortality in patients with AS (25). The EVoLVeD trial
(NCT03094143) is currently enrolling asymptomatic severe
AS patients older than 18 years old, with mid-wall late
gadolinium enhancement as an early marker of left ventricle
decompensation, to assess if early SAVR would improve
the composite outcome of all-cause mortality and AS-related
hospitalizations (33). Other interesting insights are expected
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from the EARLY-TAVR trial (NCT03042104), which started
enrollment in 2017 and is randomizing asymptomatic patients
aged 65 years or older to undergo either TAVR with the SAPIEN
3 bioprosthesis or clinical surveillance. Asymptomatic patients
are likely bound to represent the next frontier for TAVR in the
upcoming years.
Bicuspid Aortic Valve
Severe AS on a bicuspid aortic valve (BAV) shows unique features
such as presentation at an earlier age and technical issues related
to peculiar anatomical characteristics. The first landmark trial on
TAVR addressing BAV patients was published byMylotte in 2014
(mean age 78.0 ± 8.9 years), demonstrating the feasibility of a
percutaneous approach with promising outcomes on the short-
and intermediate-term, albeit with a higher incidence of post-
implantation aortic regurgitation mainly due to a more complex
anatomy compared to tricuspid valves (34). Notably, although
no differences between patients treated with TAVR with either
a bicuspid or tricuspid anatomy were evident at 30 day (35),
higher bailout TAVR-in-TAVR and lower device success rates
were reported in BAV patients; indeed, careful patient selection,
and anatomical assessment are paramount to warrant procedural
safety and long-term efficacy (36).
Based on the STS/American College of Cardiology TVT
Registry, including 81,822 consecutive patients with AS
undergoing TAVR, Makkar et al. compared 2,691 BAV patients
to a matched cohort of tricuspid aortic valve patients (median
age 74 years, mean STS score 5%) (37). Similar 30-day (2.6 vs.
2.5%) and 1-year mortality (10.5 vs. 12.0%) rates and incidence
of moderate/severe paravalvular leak at 30 days and 1 year were
reported, alongside an increased 30-day risk for stroke in patients
with BAV (2.5 vs. 1.6%) (37).
The recently published BEAT registry compared 242 BAV
patients treated with Sapien 3 vs. 111 patients treated with
Evolut R/PRO (mean age 77.8 years, mean STS score 4.4%)
and confirmed the good procedural results with both platforms
but with a higher rate of moderate-sever paravalvular aortic
regurgitation at 1 year for the Evolut R/PRO group and a more
frequent occurrence of annular rupture with balloon-expandable
valves (38). As a result, the presence of a BAV, mainly due to the
associated ellipticity of the aortic annulus, has a definite impact
of the prosthesis’ choice, as showed by a recent survey, with
current evidences supporting the adoption of a self-expandable
device (39).
Young Patients at High Surgical Risk
TAVR use is increasing rapidly among young adult patients in
recent years (40). Although TAVR may be an appealing option
for young adults with severe AS in general due to faster recovery,
avoidance of a chest scar, no need for general anesthesia, in
certain subgroups of young but frail patients TAVR might de
facto be the only feasible option due to their high surgical
risk (38). To investigate the risk profile and baseline clinical
characteristics of young patients undergoing percutaneous or
surgical treatments for severe symptomatic AS, the OBSERVANT
study analyzed data on 4,801 patients younger than 80 years
undergoing isolated TAVR or SAVR (21). The study reported a
remarkable difference in the clinical characteristics of patients
undergoing TAVR compared to those undergoing SAVR, with the
logistic EuroScore being significantly higher in TAVR patients as
compared to SAVR among all age subgroups (7.90 vs. 2.40% in
patients < 65 years, 10.57 vs. 4.91% in those aged 65–74 years
and 11.19 vs. 7.52% in patients aged 75–79 years, respectively).
Moreover, TAVR patients younger than 65 years showed the
highest short and long term mortality as compared to older
patients, mainly due to higher baseline surgical risk and frailty
rather than procedural complications (21).
The YOUNG TAVR multicenter registry described
characteristics and mortality after TAVR in different age
groups (41). Patients aged 75 years or less had significantly
higher rates of chronic obstructive pulmonary disease, diabetes
and coronary artery disease, lower ejection fraction. and slightly
higher left ventricular end-diastolic diameter compared to
intermediate (76–86 years) and older (more than 86 years)
age groups, despite having a significantly lower estimated STS
30-days mortality score (4.11 vs. 5.65 vs. 8.65% in younger,
intermediate and older age groups, respectively; p < 0.001).
Compared with younger patients, intermediate-age and older
patients showed no difference in 30-day and 1-year all-cause
mortality, but the intermediate age group showed lower all-cause
mortality at 2 years (HR, 0.62; p = 0.01). Thus, according to
clinical experience and YOUNGTAVR registry findings, “young”
patients currently treated with TAVR are a unique subgroup
with peculiar comorbidities impacting on mid-term outcomes.
Their surgical risk, however, remains only partially captured by
surgical risk scores, as age still plays a pivotal role in the STS risk
assessment (41).
These data outline that not all young patients carry a low
surgical risk but this group might hide patients that are not
suitable for any other option, as in the case of the first
patients treated by Professor Cribier. Moreover, themortality risk
assessment by means of the STS tool might be inadequate in this
young patients’ cohort. As a result, careful patient selection and
clinical assessment for TAVR treatment must be warranted in
this population to identify higher-risk individuals and guarantee
a patient-tailored treatment.
Unanswered Questions: Valve Durability,
Conduction Disturbances, and Coronary
Access
The overall encouraging and reassuring results of TAVR trials
in lower risk, younger patients must be faced against the risk
of procedural complications and unanswered questions coming
with the TAVR procedures.
TAVR durability and efficacy in younger patients with fewer
comorbidities and longer life-expectancy have been questioned
(42). TAVR long-term follow-up data mainly derive from
studies performing TAVR with early generation devices on
high or intermediate surgical risk patients and results are
hardly extendable to current low-risk patients with newer valve
prostheses. For instance, the NOTION trial randomized low
surgical risk patients (mean age 79.4 years) with severe AS to
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TAVR or SAVR in a 1:1 fashion and described similar rates of all-
cause mortality at 6 years (42.5 vs. 37.7%, respectively, P = 0.58)
with higher rates of structural valve deterioration for SAVR than
TAVR (24.0 vs. 4.8%, respectively; P < 0.001) (43). Nevertheless,
all TAVR patients received a CoreValve bioprosthesis and results
may hardly be generalizable to balloon-expandable or newer-
generation self-expanding valves. Long-term outcomes of the
PARTNER 1 trial demonstrated similar all-cause mortality at 5-
years follow-up for TAVR and SAVR (67.8 vs. 62.4%; P = 0.76)
with higher rates of moderate or severe aortic regurgitation in the
TAVR group compared to SAVR (14 vs. 1%; P < 0.0001), which
was associated with increased 5-years risk of all-cause death in the
TAVR group (44). A recent meta-analysis on structural durability
of TAVR with both balloon-expandable and self-expanding
valves vs. SAVR showed high rates of paravalvular regurgitation,
moderate or severe aortic regurgitation, and reintervention at
5-years follow-up in the TAVR group compared to SAVR, thus
highlighting that valve deterioration is still one of the open issues
of percutaneous devices (45). Again, data were derived from
trials using earlier generation TAVR valves in higher surgical risk
(46, 47). Bioprosthetic valve failure and severe structural valve
deterioration rates have been estimated to be around 4.6 and 1.3%
at long-term follow-up, respectively (48).
The clinical impact of conduction disturbances after TAVR
has been largely debated as well. High grade atrio-ventricular
block and new-onset left bundle branch block are the most
frequent complications following TAVR (49). Apart from
the mechanical interaction between the prosthesis and the
conduction system, there is evidence supporting the association
between severe aortic stenosis itself, causing calcium deposition
on the conduction system and the development of left ventricular
dysfunction, and conduction disturbances.
The 2020 SOLVE-TAVI trial comparing newer generation self-
expanding vs. balloon-expandable valves in TAVR procedures
showed a near-significant trend toward higher permanent
pacemaker implantation rate at 30 days in the self-expanding
group and compared to the balloon-expanding group (23.0 vs.
19.2%, P= 0.06) (26). A meta-analysis of 30 studies reported that
new-onset persistent left bundle branch block and permanent
pacemaker implantation after TAVR are associated with an
increased risk of death and heart failure hospitalization at 1
year, while periprocedural new-onset left bundle branch block
was also associated with higher cardiac mortality and pacemaker
implantation rates within the year following the procedure (50).
As morbidity and mortality associated with these conditions are
not trivial, careful patient evaluation and selection for TAVR
procedures, in particular in the younger patients subgroups, are
paramount (51).
TAVR assessment in younger patients must also take into
account that their longer life expectancy might require future
percutaneous procedures, either coronary or valvular or both.
This undoubtedly impacts on valve selection, as prostheses
allowing rapid and effective access to the coronary arteries or
eventual valve-in-valve TAVR shall be preferred (39). Due to
the peculiar design of most prostheses, current self-expandable
devices might hamper the access to coronary ostia and thus limit
the possibility of future percutaneous coronary interventions,
which comes as a relevant prognostic drawback in the setting of
acute coronary syndromes.
CONCLUSIONS
Adoption of a percutaneous approach for the treatment of
severe AS in progressively younger patients is one of the latest
trends in contemporary interventional cardiology. As detailed in
our review, different subgroups of patients with their peculiar
clinical characteristics are currently encountered in clinical
practice. In particular, the paradigm shift from a symptomatic
to a “prophylactic” treatment of severe AS represents one of
the major challenges of modern cardiology, radically changing
the decision-making process in the treatment of valvular heart
diseases. While opening newer therapeutic possibilities and
potentially amplifying the prognostic approach of surgical and
percutaneous treatments, this paradigm shift will challenge
operators to achieve absolute procedural safety and ascertained
long-term efficacy.
As severe AS is a complex pathology requiring comprehensive
clinical and instrumental multidisciplinary evaluation and to
date, no single algorithm can provide a patient-tailored approach,
the Heart Team plays an essential role in deciding the
optimal treatment strategy, especially when treating young
patients with scarce data guiding the decision-making process.
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